Navigation Links
Christopher and Dana Reeve Foundation Response to FDA Clearance of Geron's Clinical Trial
Date:1/23/2009

SHORT HILLS, N.J., Jan. 23 /PRNewswire-USNewswire/ -- Peter T. Wilderotter, president and CEO of the Christopher & Dana Reeve Foundation, issued the following statement today in response to FDA clearance of Geron's human clinical trial of embryonic stem cell-based therapy:

"This is an exciting first step for Geron and for spinal cord injured patients whose lives may improve due to advances in medical research. There has been so much speculative and unsubstantiated information about the use of stem cells in spinal cord injury; it is important to study these cells in a rigorously designed clinical trial that is monitored by the FDA."

Wilderotter continued, "Christopher and Dana Reeve brought national attention to this issue and they gave voice to all those who are suffering the devastating physical, emotional and financial impact of challenging neurological conditions. Their belief in the promise of stem cell research became a part of their lasting legacy."

Shortly before his death, Christopher Reeve wrote, "It is our responsibility to do everything possible to protect the quality of life of the present and future generations...No obstacle should stand in the way of responsible investigation of their [stem cells] possibilities."

Wilderotter concluded, "This is the dawn of basic research being translated into human clinical trials for people living with spinal cord injury. We are hopeful that what is learned from the results will enable us to move forward with therapies for people living with spinal cord injuries."

About the Reeve Foundation

The Christopher and Dana Reeve Foundation is dedicated to curing spinal cord injury by funding innovative research, and improving the quality of life for people living with paralysis through grants, information and advocacy. For more information, and to review the entire list of Quality of Life grant recipients, please visit our website at www.ChristopherReeve.org or call 800-225-0292.


'/>"/>
SOURCE The Christopher and Dana Reeve Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
4. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
5. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
8. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
9. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
10. HEALTHeCAREERS Network Pledges $15,000 to ASRT Foundation for Professional Healthcare Training
11. Stem Cell Sciences Enters into Services Agreement with Huntingdons Disease Research Group, CHDI Foundation Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today provided an update on the Company,s cases ... Texas and announcing that those ... Re-examination ("IPR") proceedings that VTech and Uniden filed ... on only certain claims of two of the patents ...
(Date:2/3/2016)... Feb. 3, 2016   ViaCyte, Inc ., ... first pluripotent stem cell-derived islet replacement therapy for ... development, today announced that ViaCyte and Janssen Biotech, ... Johnson & Johnson, have agreed to consolidate the ... The agreement provides ViaCyte with an exclusive license ...
(Date:2/3/2016)... N.J. , Feb. 3, 2016 ... totaling more than $1 million for researchers in ... working on health-related research that demonstrates exciting potential. ... round of funding for the New Jersey Health Foundation ... faculty members at these educational institutions— Princeton University, ...
(Date:2/3/2016)... MEDFORD, Mass. , Feb. 3, 2016  Silk Therapeutics, ... A2 financing round. Silk Therapeutics has now raised a total ... progress made by the company. The Series A2 round was ... Foxboro, Massachusetts , with participation from new investors Lear ... Sheri and Roy P. Disney ; Richard Sackler ...
Breaking Biology Technology:
(Date:1/20/2016)... 2016 A market that just keeps on ... the explosion in genomics knowledge. Learn all about it ... range of dynamic trends are pushing market growth and ... - pharmacogenomics - pathogen evolution - next generation sequencing ... greater understanding of the role of genetic material in ...
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
(Date:1/8/2016)... , January 8, 2016 NXTD ... and WorldVentures ® , a privately held leading direct ... Inc. 5000 fastest-growing company announced that on ... of $2 million in Nxt-ID to develop a proprietary ... Nxt-ID,s Wocket ® , a unique smart wallet that ...
Breaking Biology News(10 mins):